Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, Yamaguchi K, Moriguchi M, Sogame Y, Yasuda H, Iwasaku M, Konishi H, Takayama K, Itoh Y. Sakakida T, et al. Among authors: iwasaku m. J Gastroenterol. 2023 Jun;58(6):575-585. doi: 10.1007/s00535-023-01986-9. Epub 2023 Apr 7. J Gastroenterol. 2023. PMID: 37029223 Free PMC article.
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).
Iwasaku M, Uchino J, Yamada T, Chihara Y, Shimamoto T, Tamiya N, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Transl Lung Cancer Res. 2019 Aug;8(4):519-523. doi: 10.21037/tlcr.2019.08.03. Transl Lung Cancer Res. 2019. PMID: 31555524 Free PMC article.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Onoi K, et al. Among authors: iwasaku m. J Clin Med. 2020 May 6;9(5):1362. doi: 10.3390/jcm9051362. J Clin Med. 2020. PMID: 32384677 Free PMC article. Review.
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
Yamada T, Uchino J, Chihara Y, Shimamoto T, Iwasaku M, Tamiya N, Kaneko Y, Kiyomi F, Takayama K. Yamada T, et al. Among authors: iwasaku m. Ther Adv Med Oncol. 2020 May 28;12:1758835920927841. doi: 10.1177/1758835920927841. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32536981 Free PMC article.
81 results